Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dizal Pharmaceutical Co's revenue for the
three
months ended in Jun. 2026 was ¥270.2 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥968.8 Mil.
Dizal Pharmaceutical Co's Revenue per Share for the
three
months ended in Jun. 2026 was ¥0.56.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥2.09.
During the past 8 years, Dizal Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 210.50% per year. The lowest was 42.80% per year. And the median was 126.65% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dizal Pharmaceutical Co Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's Revenue distribution charts can be found below:
* The bar in red indicates where Dizal Pharmaceutical Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥968.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dizal Pharmaceutical Co (SHSE:688192) has a Revenue of ¥968.8 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Dizal Pharmaceutical Co and its competitors.
Is Dizal Pharmaceutical Co's Revenue too high?
Dizal Pharmaceutical Co's current Revenue is ¥968.8 Mil. Overall, Dizal Pharmaceutical Co has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's Revenue compare to ZTS?
Dizal Pharmaceutical Co's Revenue of ¥968.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Dizal Pharmaceutical Co and its competitors. Dizal Pharmaceutical Co's current Revenue is ¥968.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥116.88, compared to a current price of ¥57.79 — trading 50.6% below its estimated fair value. The current Revenue is ¥968.8 Mil. Dizal Pharmaceutical Co's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current Revenue is ¥968.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥57.79 is trading 50.6% below its estimated GF Value™ of ¥116.88.
GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:688192:
Revenue: ¥968.8 Mil
GF Value™: ¥116.88 vs. price of ¥57.79 (50.6% below fair value)
No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
38GF Score
Get the complete analysis for SHSE:688192
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688192 has been successfully added to your 
